[1] F.M. Gomez-Soto, J.L. Andrey, A.A. Garcia-Egido, et al., Incidence and mortality of heart failure: a community-based study, Int. J. Cardiol. 151 (2011) 40–45, https:// doi.org/10.1016/j.ijcard.2010.04.055.
[2] E. Tanai, S. Frantz, Pathophysiology of heart failure, Compr. Physiol. 6 (2015) 187–214, https://doi.org/10.1002/cphy.c140055.
[3] G.F. Mendez, M.R. Cowie, The epidemiological features of heart failure in developing countries: a review of the literature, Int. J. Cardiol. 80 (2001) 213–219, https://doi.org/10.1016/s0167-5273(01)00497-1.
[4] E. Braunwald, Heart failure, JACC Heart Fail. 1 (2013) 1–20, https://doi.org/ 10.1016/j.jchf.2012.10.002.
[5] V. Katritch, V. Cherezov, R.C. Stevens, Structure-function of the G protein-coupled receptor superfamily, Annu. Rev. Pharmacol. Toxicol. 53 (2013) 531–556, https:// doi.org/10.1146/annurev-pharmtox-032112-135923.
[6] A.S. Hauser, M.M. Attwood, M. Rask-Andersen, H.B. Schioth, ¨ D.E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications, Nat. Rev. Drug Discov. 16 (2017) 829–842, https://doi.org/10.1038/nrd.2017.178.
[7] N. Wettschureck, S. Offermanns, Mammalian G proteins and their cell type specific functions, Physiol. Rev. 85 (2005) 1159–1204, https://doi.org/10.1152/ physrev.00003.2005.
[8] M. Kang, K.Y. Chung, J.W. Walker, G-protein coupled receptor signaling in myocardium: not for the faint of heart, Physiology 22 (2007) 174–184, https://doi. org/10.1152/physiol.00051.2006.
[9] L.A. Capote, R. Mendez Perez, A. Lymperopoulos, GPCR signaling and cardiac function, Eur. J. Pharmacol. 763 (2015) 143–148, https://doi.org/10.1016/j. ejphar.2015.05.019.
[10] J.B. Regard, I.T. Sato, S.R. Coughlin, Anatomical profiling of G protein-coupled receptor expression, Cell 135 (2008) 561–571, https://doi.org/10.1016/j. cell.2008.08.040.
[11] M. Volpe, S. Rubattu, A. Battistoni, ARNi: a novel approach to counteract cardiovascular diseases, Int. J. Mol. Sci. 20 (2019), https://doi.org/10.3390/ ijms20092092 (Ar.Ni:).
[12] J. Tamargo, J. Lopez-Send ´ on, ´ Novel therapeutic targets for the treatment of heart failure, Nat. Rev. Drug Discov. 10 (2011) 536–555, https://doi.org/10.1038/ nrd3431.
[13] T. Tsuda, M. Takefuji, N. Wettschureck, et al., Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction, J. Exp. Med. 214 (2017) 1877–1888, https://doi.org/10.1084/jem.20161924.
[14] M. Takefuji, T. Murohara, Corticotropin-releasing hormone family and their receptors in the cardiovascular system, Circ. J. 83 (2019) 261–266, https://doi. org/10.1253/circj.CJ-18-0428.
[15] O. Toman, K. Hnatkova, P. Smetana, et al., Physiologic heart rate dependency of the PQ interval and its sex differences, Sci. Rep. 10 (1) (2020) 2551.
[16] P. Indraratna, D. Tardo, M. Delves, R. Szirt, B. Ng, Measurement and management of QT interval prolongation for general physicians, J. Gen. Intern. Med. 35 (2020) 865–873, https://doi.org/10.1007/s11606-019-05477-7.
[17] M. Takefuji, M. Krüger, K.K. Sivaraj, K. Kaibuchi, S. Offermanns, N. Wettschureck, RhoGEF12 controls cardiac remodeling by integrating G protein- and integrindependent signaling cascades, J. Exp. Med. 210 (2013) 665–673, https://doi.org/ 10.1084/jem.20122126.
[18] A.C. deAlmeida, R.J. van Oort, X.H. Wehrens, Transverse aortic constriction in mice, J. Vis. Exp. 38 (2010), https://doi.org/10.3791/1729.
[19] J.A. Doust, E. Pietrzak, A. Dobson, P. Glasziou, How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review, BMJ 330 (2005) 625, https://doi.org/10.1136/bmj.330.7492.625.
[20] A.M. Katz, Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure, New Engl. J. Med. 322 (1990) 100–110, https://doi.org/ 10.1056/NEJM199001113220206.
[21] J.S. Borer, S. Truter, E.M. Herrold, et al., Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload, Circulation 105 (2002) 1837–1842, https://doi.org/10.1161/01.cir.0000014419.71706.85.
[22] M. Rask-Andersen, S. Masuram, H.B. Schioth, ¨ The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication, Annu. Rev. Pharmacol. Toxicol. 54 (2014) 9–26, https://doi.org/10.1146/ annurev-pharmtox-011613-135943.
[23] B.C. Heng, D. Aubel, M. Fussenegger, An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases, Biotechnol. Adv. 31 (2013) 1676–1694, https://doi.org/10.1016/j. biotechadv.2013.08.017.
[24] T. Kishimoto, R.V. Pearse 2nd, C.R. Lin, M.G. Rosenfeld, A sauvagine/ corticotropin-releasing factor receptor expressed in heart and skeletal muscle, Proc. Natl. Acad. Sci. USA 92 (1995) 1108–1112, https://doi.org/10.1073/ pnas.92.4.1108.
[25] A.Y. Abuhelwa, D.B. Williams, R.N. Upton, D.J. Foster, Food, gastrointestinal pH, and models of oral drug absorption, Eur. J. Pharm. Biopharm. 112 (2017) 234–248, https://doi.org/10.1016/j.ejpb.2016.11.034.
[26] A. Rühmann, I. Bonk, C.R. Lin, M.G. Rosenfeld, J. Spiess, Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30, Proc. Natl. Acad. Sci. USA 95 (1998) 15264–15269, https://doi.org/10.1073/pnas.95.26.15264.
[27] G.B. Santos, A. Ganesan, F.S. Emery, Oral administration of peptide-based drugs: beyond Lipinski’s rule, ChemMedChem 11 (2016) 2245–2251, https://doi.org/ 10.1002/cmdc.201600288.
[28] D.G. Parkes, J. Vaughan, J. Rivier, W. Vale, C.N. May, Cardiac inotropic actions of urocortin in conscious sheep, Am. J. Physiol. 272 (1997) H2115–H2122, https:// doi.org/10.1152/ajpheart.1997.272.5.H2115.
[29] J.C. Hancox, M.J. McPate, A. El Harchi, Y.H. Zhang, The hERG potassium channel and hERG screening for drug-induced torsades de pointes, Pharmacol. Ther. 119 (2008) 118–132, https://doi.org/10.1016/j.pharmthera.2008.05.009.
[30] G. Erdemli, A.M. Kim, H. Ju, C. Springer, R.C. Penland, P.K. Hoffmann, Cardiac safety implications of hNav1.5 blockade and a framework for pre-clinical evaluation, Front. Pharmacol. 3 (2012) 6, https://doi.org/10.3389/ fphar.2012.00006.
[31] S.C. Coste, R.A. Kesterson, K.A. Heldwein, et al., Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2, Nat. Genet. 24 (2000) 403–409, https://doi.org/10.1038/ 74255.
[32] C.Y. Chen, M.L. Doong, J.E. Rivier, Y. Tach´e, Intravenous urocortin II decreases blood pressure through CRF(2) receptor in rats, Regul. Pept. 113 (2003) 125–130, https://doi.org/10.1016/s0167-0115(03)00003-x.
[33] B. Mayr, M. Montminy, Transcriptional regulation by the phosphorylationdependent factor CREB, Nat. Rev. Mol. Cell Biol. 2 (2001) 599–609, https://doi. org/10.1038/35085068.
[34] C.A. Saura, J.R. Cardinaux, Emerging roles of CREB-regulated transcription coactivators in brain physiology and pathology, Trends Neurosci. 40 (2017) 720–733, https://doi.org/10.1016/j.tins.2017.10.002.
[35] J. Tasoulas, L. Rodon, F.J. Kaye, M. Montminy, A.L. Amelio, Adaptive transcriptional responses by CRTC coactivators in cancer, Trends Cancer 5 (2019) 111–127, https://doi.org/10.1016/j.trecan.2018.12.002.
[36] W.A. Sands, T.M. Palmer, Regulating gene transcription in response to cyclic AMP elevation, Cell. Signal. 20 (2008) 460–466, https://doi.org/10.1016/j. cellsig.2007.10.005.
[37] D. Guo, Z. Kassiri, R. Basu, et al., Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress, Circ. Res. 107 (2010) 1275–1289, https://doi.org/10.1161/CIRCRESAHA.110.229054.
[38] P.T. Chien, C.C. Lin, L.D. Hsiao, C.M. Yang, c-Src/Pyk2/EGFR/PI3K/Akt/CREBactivated pathway contributes to human cardiomyocyte hypertrophy: role of COX2 induction, Mol. Cell. Endocrinol. 409 (2015) 59–72, https://doi.org/10.1016/j. mce.2015.04.005.
[39] J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nat. Rev. Genet. 7 (2006) 606–619, https://doi.org/10.1038/nrg1879.
[40] I. Shimizu, T. Minamino, Physiological and pathological cardiac hypertrophy, J. Mol. Cell. Cardiol. 97 (2016) 245–262, https://doi.org/10.1016/j. yjmcc.2016.06.001.
[41] H.A. Rockman, W.J. Koch, R.J. Lefkowitz, Seven-transmembrane-spanning receptors and heart function, Nature 415 (2002) 206–212, https://doi.org/ 10.1038/415206a.
[42] M. Iwase, M. Uechi, D.E. Vatner, et al., Cardiomyopathy induced by cardiac Gs alpha overexpression, Am. J. Physiol. 272 (1997) H585–H589, https://doi.org/ 10.1152/ajpheart.1997.272.1.H585.
[43] E. Braunwald, Expanding indications for beta-blockers in heart failure, New Engl. J. Med. 344 (2001) 1711–1712, https://doi.org/10.1056/ NEJM200105313442210.
[44] M. Packer, M.R. Bristow, J.N. Cohn, et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, New Engl. J. Med. 334 (1996) 1349–1355, https://doi.org/10.1056/ NEJM199605233342101.
[45] C. Monteiro-Pinto, R. Adao, ˜ A.F. Leite-Moreira, C. Bras-Silva, ´ Cardiovascular effects of Urocortin-2: pathophysiological mechanisms and therapeutic potential, Cardiovasc. Drugs Ther. 33 (2019) 599–613, https://doi.org/10.1007/s10557- 019-06895-9.